Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Aplagon Oy
Sponsor

Aplagon Oy

Finland Tukholmankatu 8 A, 00290 Helsinki, Finland

About the sponsor

Clinical research in peripheral arterial occlusive disease and peripheral arterial occlusive disease (PAOD), with a focus on blood flow impairment in the lower limbs.

  • Peripheral arterial occlusive disease
  • Peripheral arterial occlusive disease (PAOD)

The sponsor’s work in this area centers on vascular conditions associated with reduced arterial perfusion and limb ischemia.

About Specializations

Aplagon Oy runs clinical trials in conditions such as Peripheral arterial occlusive disease, End stage renal disease, Chronic kidney disease, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

2 clinical trials

Peripheral arterial occlusive disease

Recruiting

Study of APAC (antiplatelet, anticoagulant) treatment in patients with peripheral arterial disease and chronic limb-threatening ischemia during blood vessel restoration procedure

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Heparin Sodium
  • Sponsor:Aplagon Oy

End stage renal disease+1

Not yet recruiting

Safety and efficacy of locally administered APAC, heparin sodium and sodium chloride to promote arteriovenous fistula maturation in patients with end‑stage kidney disease

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Heparin Sodium
  • Sponsor:Aplagon Oy

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.